Matthias Muller-Gliemann

This inventor holds 35 USPTO granted patents, primarily in Heterocyclic Compounds. Top assignee: Bayer Aktiengesellschaft. Active years: 1993-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matthias Muller-Gliemann. Retrieved from https://idiyas.com/inventor/matthias-muller-gliemann

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 35

% Patents Active = 100.0

Average Co-Inventor Count = 12.4

ph-index = 12

Forward Citations = 397(Granted Patents)

Location History:

Wuppertal, DE (1993 - 1998)
Solingen-Ohligs, DE (1993 - 1999)
Solingen, DE (1995 - 2000)

Company Filing History:

35 out of 12,269

Bayer Aktiengesellschaft

patents

Years Active: 1993-2000

Loading Chart...

Areas of Expertise:

Pyridines

Phenylacetamides

Imidazoles

Heterocycles

Cyclohexanes

Biphenyls

Carboxylic Acids

Propenoic Acids

Medicaments

Substituted Compounds

Angiotensin II Receptor

Derivatives

35 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6127383 - 2-aryl-substituted pyridines (2000-10-03),

2. 6121330 - 5-Hydroxyalkyl substituted phenyls and their use in medicaments for the (2000-09-19),

3. 6069148 - Cycloalkano-pyridines (2000-05-30),

4. 5935983 - Use of phenylcyclohexylcarboxamides (1999-08-10),

5. 5932587 - Heterocyclic-fused pyridines (1999-08-03),

6. 5925645 - 2-aryl-substituted pyridines (1999-07-20),

7. 5863930 - Trisubstituted biphenyls (1999-01-26),

8. 5834481 - Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid (1998-11-10),

9. 5776964 - Heterocyclically substituted phenylacetic acid derivatives and their use (1998-07-07),

10. 5712296 - Substituted pyridines and 2-oxo-1,2-dihydropyridines (1998-01-27),

11. 5708003 - Heterotricyclically substituted phenyl-cyclohexane-carboxylic acid (1998-01-13),

12. 5693650 - 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives (1997-12-02),

13. 5530016 - Substituted 2,4-imidazolidinediones (1996-06-25),

14. 5527809 - Substituted imidazo[4,5-b]pyridines and benzimidazoles (1996-06-18),

15. 5521206 - Heterocyclically substituted phenylacetic acid derivatives and their use (1996-05-28),

Title: Innovations by Matthias Muller-Gliemann: A Leader in Pharmaceutical Patents

Introduction: Matthias Muller-Gliemann, located in Solingen, Germany, is a prominent inventor with an impressive portfolio of 35 patents. His contributions to pharmaceutical innovation have significantly impacted the development of new medicaments, especially in treating serious conditions like arteriosclerosis.

Latest Patents: Among his notable recent inventions are the 2-aryl-substituted pyridines. These compounds are synthesized through the reaction of pyridylaldehydes with organometallic compounds, followed by selective reduction. The resulting 2-aryl-substituted pyridines have shown great potential as active ingredients in medicaments, specifically targeting treatments for arteriosclerosis. Additionally, he has worked on 5-hydroxyalkyl substituted phenyls and their medicinal applications.

Career Highlights: Matthias Muller-Gliemann is associated with Bayer Aktiengesellschaft, where he contributes his expertise in medicinal chemistry. His extensive work focuses on developing innovative compounds that can advance the pharmaceutical industry and provide solutions for critical health issues.

Collaborations: Throughout his career, Matthias has collaborated with talented colleagues such as Stefan Wohlfeil and Ulrich E Muller, fostering a dynamic environment for creative solutions in drug development. These professional partnerships have further enhanced the quality and effectiveness of the innovations produced.

Conclusion: Matthias Muller-Gliemann continues to be a driving force in the realm of pharmaceutical inventions. His innovative approaches and collaboration with esteemed colleagues position him at the forefront of developing impactful treatments for various medical conditions. His contributions to the field will undoubtedly pave the way for future advancements in healthcare.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]